Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis

This study has been completed.
Ligue Pulmonaire Genevoise
Information provided by:
University Hospital, Geneva Identifier:
First received: January 7, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted
New blood tests have become available to detect either latent or active tuberculosis. These tests - which according to the CDC can replace the tuberculin skin test - measure the production of gamma-interferon (a cytokine) by peripheral lymphocytes (white cells) when exposed to antigens which are highly specific of mycobacterium tuberculosis (the bacteria responsible for tuberculosis). Our hypothesis was that the production of gamma-interferon would be much higher at the beginning of treatment than at the end, and that decline in gamma-interferon secretion could be an indicator of clinical response to treatment.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study of Production of IFN-Gamma by Peripheral Lymphocytes in Response to Specific Antigens Before and After Treatment for Tuberculosis

Resource links provided by NLM:

Further study details as provided by University Hospital, Geneva:

Primary Outcome Measures:
  • Interferon gamma response to M. tuberculosis antigens by peripheral lymphocytes after treatment for tuberculosis [ Time Frame: 12-18 months ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA
Peripheral blood lymphocytes cultured over-night; ELISPOT for detection of interferon-gamma production

Enrollment: 89
Study Start Date: October 2004
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Patients either treated for active culture proven tuberculosis (TB) or having completed treatment during the preceding 6 months were recruited. Exclusion criteria were : HIV infection and previous TB. Interferon gamma release assay (T-SPOT.TB, Oxford Immunotec) was sampled during the 2 first weeks of treatment, at the end of treatment and 6 months later.

T-SPOT.TB was analysed qualitatively (pos/neg) and quantitatively (Spot forming units: SFU) to determine if there was a higher rate of negative tests at the end of treatment and 6 months after treatment than initially. Paired samples were analysed to compare SFU counts between beginning of treatment and end of treatment, and SFU counts between end of treatment and 6 months later.

Clinical response to treatment was recorded, as well as treatment failures and relapses.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients either at diagnosis of tuberculosis, under treatment for tuberculosis, or within 6 months after treatment completion

Inclusion Criteria:

  • culture proven tuberculosis

Exclusion Criteria:

  • age < 18
  • prior tuberculosis
  • HIV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00595907

Centre antituberculeux; Geneva University Hospital
Geneva, Geneva 14, Switzerland, 1211
Sponsors and Collaborators
University Hospital, Geneva
Ligue Pulmonaire Genevoise
Principal Investigator: Jean-Paul Janssens, M.D. Geneva University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jean-Paul Janssens, MD Identifier: NCT00595907     History of Changes
Other Study ID Numbers: Janssens1/2008 
Study First Received: January 7, 2008
Last Updated: January 7, 2008
Health Authority: Switzerland: Ethikkommission

Keywords provided by University Hospital, Geneva:
interferon gamma release assays

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on October 21, 2016